Vorinostat
Brain Neoplasm
H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
62 Active assets in the Brain Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib M.D. Anderson Cancer Center | Phase 2 | BBB |
Temsirolimus M.D. Anderson Cancer Center | Phase 2 | BBB |
Sorafenib National Cancer Institute (NCI) | Phase 2 | BB |
Dexmedetomidine Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 4 | BB |
Nivolumab InSightec | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Vorinostat is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BB
Indicative · Phase 2
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →